跳至主要内容
临床试验/NCT03425578
NCT03425578已完成不适用

Glutamate Supplementation and Its Effects on Skeletal Muscle Glucose Metabolism During an Oral Glucose Challenge in Healthy Young Men

University of Waterloo2 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2018年3月19日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
11
试验地点
2
主要终点
Glutamate

研究概览

简要总结

Amino acids play an important role in human metabolism. In aging individuals and in some diseases, certain amino acids, such as glutamate, are at lower than normal levels. Glutamate appears to be involved in providing energy and maintaining normal blood sugar (glucose) levels, processes which both depend heavily on skeletal muscle. The maintenance of healthy blood sugar levels, in particular, is tightly related to overall muscle mass and quality. To better understand the link between glutamate and glucose metabolism in skeletal muscle, the investigators will be using a nutritional approach to raise the body's glutamate levels with monosodium glutamate (MSG) supplementation, and raise blood glucose levels with a sugary drink. By altering the normal levels of glutamate and glucose in the blood and muscle tissue, the investigators can gather more information about the role of glutamate in energy metabolism. This will help the design of future studies investigating the function of glutamate in aging and disease. During this study the investigators will increase the levels of glutamate and glucose in the bloodstream by asking participants to ingest MSG along with a sugary drink. The goal is to subsequently determine: A) the amount of glutamate and glucose that ends up in the muscle; and B) whether normal skeletal muscle glucose metabolism, and the behaviour of additional amino acids (other than glutamate) is altered. The hypothesis is that when MSG and sugar drink are ingested together glucose uptake and metabolism within the skeletal muscle will be elevated.

详细描述

Glutamate is involved in several aspects of glucose metabolism in both muscle and liver, however its role has not been fully defined. It is the primary amino acid taken up by resting and exercising skeletal muscle, where it interacts with pyruvate (derived from glycolysis) to produce the TCA cycle intermediate 2-oxoglutarate and the gluconeogenic precursor alanine. Glutamate is also required for the production of glutamine, another gluconeogenic precursor, via intramuscular reactions with ammonia. Given that skeletal muscle is responsible for 85% of whole body glucose disposal, investigating the interplay between glutamate, its related amino acids, and glucose homeostasis is of particular relevance. However, despite its many links to energy provision, the role of glutamate in skeletal muscle glucose metabolism remains poorly understood.

Few studies have manipulated circulating concentrations of both glutamate and glucose in humans, and none have evaluated the effect of this unique manipulation in skeletal muscle tissue. In healthy young adults, a dose of roughly 10 g monosodium glutamate (MSG) transiently elevates plasma (700-800%) and intramuscular (30%) glutamate concentrations. Acute MSG supplementation also stimulates modest increases in plasma concentrations of aspartate, alanine, and glutamine (which are produced from glutamate within the muscle and subsequently released into circulation). Intriguingly, insulin is secreted in response to MSG supplementation, an effect that appears to be mediated by glutamate binding to an excitatory amino acid receptor on the pancreas. In addition to its action on the pancreas, there is some evidence to suggest that glutamate may function as a secondary messenger by enhancing glucose-stimulated insulin secretion during periods of increased carbohydrate (CHO) availability. However this secondary effect of glutamate on insulin is poorly understood.

The ability of glutamate to independently stimulate insulin secretion provides further support for an association between glutamate and glucose metabolism, yet only two studies to date have administered MSG during an oral glucose challenge to directly examine this relationship. One study observed no effect of MSG on glucose tolerance, however peak plasma glutamate was dramatically blunted in this study compared to previous reports (~ 80 vs. 400-500 µM), likely due to glutamate being retained in the gut as a result of co-ingestion with CHO. In a separate study, the authors developed a methodological approach to circumvent this issue: by staggering the administration of MSG and CHO by 30 min, plasma glutamate and glucose were both significantly and simultaneously elevated. Furthermore, MSG administration improved glucose tolerance. In support of these findings, improvements in glucose clearance following a high-fat meal combined with MSG has also been reported. Interestingly, not all studies have observed enhanced insulin secretion with higher glutamate availability. This suggests that the ability of carbohydrate to stimulate insulin secretion may overpower any effect of glutamate on this hormone, but the specific mechanisms remain to be fully elucidated.

Recently, investigators have developed a cell culture model to show that glutamate stimulates glucose uptake in rat L6 myotubes in the absence of insulin. This suggests that glutamate is capable of acting directly on skeletal muscle, and supports previous findings of improved glucose tolerance with acute MSG supplementation despite no further increase in insulin secretion. Additionally, cell data demonstrates that glutamate-stimulated glucose uptake results from increased glucose transporter 4 (GLUT4) translocation to the sarcolemma, via the activation of AMP-activated protein kinase (AMPK) and p38 mitogen-activated protein kinase (MAPK). It is possible that these mechanisms underpin glutamate-mediated improvements in glucose tolerance in humans. However, this - as well as the fate of glucose upon being taken up by the muscle cell - has yet to be investigated.

There is a high degree of interplay between glutamate and glucose metabolism, but it remains unclear whether elevated plasma concentrations of glutamate and glucose influence one another's uptake into human skeletal muscle, as well as their subsequent respective intramuscular metabolic reactions. Therefore, the overarching goal of this study is to uncover the effects of acute MSG+CHO supplementation on plasma and intramuscular amino acid concentrations, as well as aspects of skeletal muscle glucose metabolism, in healthy young men in comparison to the ingestion of MSG and CHO alone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • BMI in the normal or overweight range (18.5-30.0 kg/m2)
  • Weight stable for the past 6 months
  • Participate in aerobic and/or resistance-type exercise 3-5 times per week (no more then 2 hours per session and/or 5 sessions per week)
  • Fasting blood glucose < 6.0 mM
  • Resting blood pressure < 140/90 mmHg
  • Answer "no" to all questions on the Get Active Questionnaire (GAQ)

排除标准

  • Known allergy or intolerance to MSG
  • Diabetes, cancer, or other metabolic disorders
  • Cardiac or gastrointestinal problems
  • Infectious disease
  • Injuries that prevent safe participation and exercise or instructions from healthcare provider to refrain from exercise
  • Barium swallow or nuclear medicine scan in the previous 3 weeks
  • If receiving a DXA scan will cause the participant to exceed the maximum trivial dose of radiation per year
  • Prescription anti-coagulant or anti-platelet medication (e.g. warfarin, heparin, clopiodogrel)

研究组 & 干预措施

MSG + placebo B

Active Comparator

Participants will ingest 150 mg/kg body mass monosodium glutamate followed by a non-caloric, flavoured placebo.

干预措施: MSG (Dietary Supplement)

MSG + CHO

Experimental

Participants will ingest 150 mg/kg body mass monosodium glutamate followed by 75 g dextrose.

干预措施: MSG (Dietary Supplement)

Placebo A + CHO

Active Comparator

Participants will ingest placebo capsules followed by 75 g dextrose.

干预措施: CHO (Dietary Supplement)

MSG + CHO

Experimental

Participants will ingest 150 mg/kg body mass monosodium glutamate followed by 75 g dextrose.

干预措施: CHO (Dietary Supplement)

Placebo A + CHO

Active Comparator

Participants will ingest placebo capsules followed by 75 g dextrose.

干预措施: Placebo A (Dietary Supplement)

MSG + placebo B

Active Comparator

Participants will ingest 150 mg/kg body mass monosodium glutamate followed by a non-caloric, flavoured placebo.

干预措施: Placebo B (Dietary Supplement)

结局指标

主要结局

Glutamate

时间窗: ~ 2 hours post-ingestion

Circulating and intramuscular concentrations by HPLC

次要结局

  • Aspartate(~ 2 hours post-ingestion)
  • C-peptide(~ 2 hours post-ingestion)
  • Glucose(~ 2 hours post-ingestion)
  • Insulin(~ 2 hours post-ingestion)
  • Skeletal muscle glucose uptake(~ 2 hours post-ingestion)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验